摘要
目的观察缬沙坦对慢性心力衰竭(CHF)患者肾素-血管紧张素-醛固酮系统(RAAS)活性的影响。方法105例CHF患者随机分为常规治疗组47例和缬沙坦治疗组58例,50例健康体检者作为健康对照组。常规治疗组行标准抗心力衰竭治疗,缬沙坦治疗组在标准抗心力衰竭治疗的基础上加用缬沙坦。检测其血管紧张素Ⅰ和Ⅱ(AngⅠ、AngⅡ)、醛固酮、一氧化氮水平和左心室射血分数(LVEF)。结果①CHF患者LVEF降低,余均升高(均P<0.05)。②常规治疗组和缬沙坦治疗组治疗前后各指标均有显著变化(均P<0.05)。③AngⅡ与AngⅠ、醛固酮、一氧化氮呈正相关(r=0.370、P=0.004,r=0.853、P=0.000,r=0.363、P=0.005),与LVEF呈负相关(r=-0.407、P=0.002)。结论CHF存在着RAAS的过度激活,AngⅡ对心功能恶化起关键作用。缬沙坦可抑制RAAS活性,控制心力衰竭症状,改善心功能。
Objective To observe the effect of valsartan on renin-angiotensin-aldostcrone system （RAAS） in patients with chronic heart failure （ CHF）. Methods 105 patients with CHF were randomly divided into routine treatment group （ n =47 ） and valsartan treatment group （ n = 58 ） ,meanwhile ,other 50 normal subjects were enrolled as normal control group. The plasma levels of angiotensin Ⅰ （ Ang Ⅰ） , Ang Ⅱ, aldosterone （ Ald ） , NO and left ventricular enjection fraction （LVEF） were measured. Results ①The plasma levels of Ang Ⅰ, Ang Ⅱ, Ald, NO increased in patients with CHF（P 〈 0.05 for each）. LVEF decreased in CHF patients （P 〈0.05）. ②There appeared obvious changes of plasma levels of Ang Ⅰ , Ang Ⅱ, Ald, NO and LVEF in routine treatment group and valsartan treatment group （ P 〈 0.05 for each）. ③ Ang Ⅱ was positively correlated with Ang Ⅰ, Aid and NO （ R = 0.370,P = 0. 004, R = 0. 853 ,P = 0. 000, R = 0. 363, P = 0. 005 ） , while negatively correlated with LVEF （ R = -0. 407, P = 0. 002 ）. Conclusion RAAS is over activated in CHF patients and Ang Ⅱ plays a key role in the deterioration of cardiac function. Valsartan may inhibit the activity of RAAS and improve the symptoms of heart failure and cardiac function.
出处
《中国综合临床》
北大核心
2006年第7期588-590,共3页
Clinical Medicine of China
基金
宁夏医学院重点科研课题基金资助
